通過(guò)核酸標(biāo)記技術(shù)可將細(xì)胞因子cDNA作為基因探釗檢測(cè)細(xì)胞內(nèi)細(xì)胞因子基因組DNA或mRNA。主要有以下幾種方法：
1.應(yīng)用同位素（或非同位素)標(biāo)記的cDNA探針，檢測(cè)經(jīng)Northern blot后細(xì)胞因子mRNA水平或采用打點(diǎn)雜交法。
2.應(yīng)用標(biāo)記cDNA探釗與細(xì)胞或組織切片進(jìn)行原位雜交，然后進(jìn)行放射自顯影。
3.細(xì)胞因子mRNA經(jīng)反轉(zhuǎn)錄為cDNA，用特異性細(xì)胞因子引物經(jīng)聚合酶鏈反應(yīng)（PCR)擴(kuò)增細(xì)胞因子cDNA,Southern blot后用標(biāo)記探針檢測(cè)特異細(xì)胞因子DNA水平。
參 考 文 獻(xiàn)
1.Ared WP,et al.An IL-1 inhibitor from human monocytes production and characterization of biologic properties.J Immunol,1980;143:1851
2.Baggiolini M and Dahinden CA.CC chemokines in allergic inflammation.Immunol Today 1994;15(3):127
3.Balkwill FR and Burke F.The cytokine network.Immunol Today,1989;10(9):299
4.Bazan JF.Haemopoietic receptors and helical cytokines .Immunol Today,1990;11(10):350
5.Cannon J G,et al.Circulating interleukin-1 and tumor necrosis of tumors.PNAS,1975;72:3666
7.Chan SH,et al.Induction of interferon γ production by natural killer cell stimulatory factor:characterization of the responder cells and synergy with other inducers.J Exp Med,1991;173:869
8.Chen WF,et al.IL-10:A novel cytotoxic T cell diffeentiation factor.J Immunol,1991;147(2):528
9.Cosman D,et al.A new cytokine receptor superfamily.TIBS,1990;15-July:265
10.Dinarello CA.Interleukin 1 and interleukin-1antagonism.Blood,1991;77(8):1627
11.Dower SK,et al.Molecular characterization of two types of interleukin-1 recep-tor coding peptide on murine and human cells.J Leukoc Biol(suppl.),1990;1:103
12.Durum SK and Mealy K.Hilton head revisited-cytokine explosion of the80s takes shape for the 90s.Immunol Today,1990;11(4):103
13.Durum SK,et al.New cytokines and receptors nake their debut in SanAntonio.Immunol Today,1991;12(2):54
14.Edward A,et al.How B and Tcells talk to each other.Nature,1994;367:425
15.Eisenberg SP.et al.Primary structure and funtional expression from complementary DNA of a human inteleukin 1 receptor antagonist Nature,1990;3:341
16.Engelmann H,et al.A Tumor necrosis factor binding protein purified to homogeneity from human urine protects cells from tumor necrosis factor toxicity.J Biol Chem 1989;264:11974
17.Fiorentino DF,et al.IL-10 acts on the antigen-presenting cell to inhibit cytokine production by Th1 cells.J Immunol,1991;146(10):3444
18.Fong Y,et al. Antibodies to cachetin/TNF reduce IL-1β and IL-6 appearance during lethal bacteremia J Exp Med 1989;170:1627
19.Gasson JC.Molecular physiology of granulocyte-macrophage colony-stimulating factor.Blood,1991;77(6):1131
20.Gately MK,et al.Synergy between recombinant interleukin 2(r IL-2)and IL-2 depleted lymphokine containing supernatants in facilitating allogeneic human cytolytic T lymphocyte responses in vitro.j Immunol,1986;136:1274
21.Gately MK,et al.Regulation of human lymphocyte proliferation by a heterodimeric cytokine,IL-12(cyotoxic lymphocyte maturation factor).j Immunol,1991;147:874
22.Gubler V,et al.Coexpression of two distinct genesis requird to generate secreted bioactive cytotoxic lymphocyte maturation factor.PNAS,1991;88:4143
23.Hayashida K,et al.Molecular cloning of a second subunit of the receptor for human granulocyte-macrophage colony-stimulating factor(GM-CSF):reconstitution of a high-affinity GM-CSf receptor.PNAS,1990;87:9655
24.Himeno T,et al.Expression of endogenous tumor necrosis factor.Cancer Res,1990;50:4941
25.Hirano T,et al.Biological and clinical aspects of interleukin 6.Immunol Today,1990;11(12):443
26.Horuk R.The interleukin-8-receptor family:from chemokines to malaria.Immunol Today,1994;15(4):
27.Humnum CH et al.Interleukin-1 receptor antagonist activity of a human interleukin-1 inhibitor.Nature,1990;343:336
28.James K.Interaction between cytokines and α2macroglobulin.Immunol Today,1990;11(50:163
29.Kishimoto T.The biology of interleukin-6.Blood,1989;74:1
tory factor(NKSF),a cytokine with multiple biologic effects on human lymphocytes.J Exp Med 1989;170:827
31.Krantz S.Erythropoietin.Blood,1991;77(3):419
32.Liu Y and Mullbacher A.Hypothesis:immunological help is reciprocally delivered between different subpopulations of lymphocytes.Scand j Immunol,1989;30:277
33.Lowenthal JM,et al.Binding and internalization of interleukin 1 by Tcells direct evidence for high and low affinity classes of interleukin-1receptor.J Exp Med 1986;164:1060
34.Moore KW,et al.Homology of cytokine synthesis inhibtory factor(IL-10)to the Epstein-Barr virus gene BCRFI.Science,1990;248:1230
35.Morgan RA,et al.Selective in vitro growth of t lymphocytes.Science,1976;193:1007
36.Murphy PM.The molecular biology of leukocyte chemoattractant receptors.Annu Rev Immunol,1994;12:593
37.Musash M,et al.Direct and synergistic effects of interleukin 11 on murine hemopoiesis in culture.PNAS,1991;88:765
38.NacNeil IA,et al.IL-10,A novel growth factor for mature and immatureT cell.J Immunol,1990;145:4167
39.Namen AE,et al.Stimulation of B-cell progenitors by cloned murine interleukin 7.Nature,1988;33:571
40.Paul SR,et al.Molecular cloning of a cDNA encoding interleukin 11,a stromal cell-derived lymphopoietic and hematopoietic cytokine.PNAS,1990;87:7512醫(yī)學(xué)全.在線gydjdsj.org.cn
41.Pizzolo G,et al.Soluble interleukin 2 receptor in the serum of patients with Hodgkin's disease.Br J Cancer 1987;55:427
42.Ralop P.A summary of cytokine aspects of the intermational symposium of molecular hematology.1990;Lymphokine and Cytokine research,1991;10(1):77
43.Rot A.Endothelial cell binding of NAP-1/IL-8 role in neutrophil emigration.Immunol Today 1992;13(8):291
44.Rubin LA,et al.The soluble interlenkin-2 receptor biology,function and clinical application.Annals of Internal.Medicine 1990;113(8):619
45.Rubin LA,et al.Soluble interleukin 2 receptors are released from activated human lymphoid cells in vitro.J Immunol.1985;135:3172
46.Sims JE,et al.cDNA expression cloning of the IL-1 receptor,a member of the immunoglobulin superfamily.Science 1988;241:585
47.Smith KA.Interleukin-2:inception,impact and implications.Science,
1988;240:1169
48.Snouwaert JN,et al.Effects of site-specific mutations on biologic activity of recombinant human IL-6.J Immunol,1991;146(2):585
49.Stern AS,et al.Purification to homogencity and partial characterization of cytotoxic lymphocyte maturation factor from human B-lypmhoblastoid cell.PNAS,1990;87:6808
50.Stotter H,et al.IL-7induces human lymphokine-activated killer cell activity and is regulated by IL-4.J Immunol 1991;146(1):150
51.Takaki S,et al.Molecular cloning and expression of the murine interleukin-5 receptor.EMBO,1990;(13):4367
52.Taub DD and Oppenheim JJ.Review of the chemokine meeting the third international symposium of chemotactic cytokines.Cytokine,1993;5(3):175
53.Uckun FM,et al.Interleukin 7 receptor ligation stimulates tyrosine phosphorylation,inositol phospholipid turnover,and clonal proliferation ofhuman B-cell precursors.PNAS,1991;88:3589
54.Uyttenhove C,et al.Functional and structural characterization of P40,a mouse glycoprotein with T cell-growth factor activity.PNAS,1988;85:6934
55.William E,et al.Structure and functional expression of a human interleukin-8 receptor.Science,1991;253:1278
56.Wong HL,et al.Characterization of a factor(s) which synergizes with recombinant interleukin 2 promoting allogenic human cytolytic T-lymphocyte responses in vitro.Cell Immunol,1988;11:39
57.Xing X and Yong SC:Human recombinant IL-3 is a growth factor for normal B cells.J Immunol,1992;148(2):491
58.Yin T,et al.Involvement of IL-6 signal transducer gp130 in IL-11-mediated signal transduction.J Immunol,1993;151:2555
59.侯云德.干擾素的不同亞型與臨床應(yīng)用。中國(guó)生物物品學(xué)雜志1991；6（4)：145
60.曹廣文、杜平.生藥活性多糖對(duì)淋巴細(xì)胞/細(xì)胞素的調(diào)節(jié)與抗腫瘤作用。免疫學(xué)雜志，1992；8（4)：273
61.孫紅、施渭康.白血病抑制因子.細(xì)胞生物學(xué)，1994；16（2)49
62.段海清、黃翠芳.抑瘤素M研究進(jìn)展.因外醫(yī)學(xué)免疫學(xué)分冊(cè)，1994；17（4)：185
63.朱學(xué)軍、曹雪濤.腫瘤壞死因子拮抗劑的種類性質(zhì)及其治療作用.國(guó)外醫(yī)學(xué)免疫分冊(cè)，1994；17（1)：21
64.舒翠玲、金伯泉.白細(xì)胞介素12（IL-12)的研究概況.免疫學(xué)雜志，1992；8（2)：133
65.孫忱、金伯泉.可溶性細(xì)胞因子受體研究進(jìn)展.國(guó)外醫(yī)學(xué)免疫學(xué)分冊(cè)，1994；17（2)：70
66.孫凱、金伯泉.細(xì)胞因子受體中的共用鏈現(xiàn)象及信號(hào)轉(zhuǎn)導(dǎo)
67.黃傳書、金伯泉.IL-3、IL-5和GM-CSF受體研究的進(jìn)展。國(guó)外醫(yī)學(xué)免疫學(xué)分冊(cè)，1995；18（3)：121
68.張新海、金伯泉. 趨化因子研究進(jìn)展-趨化因子家族（一)。國(guó)外醫(yī)學(xué)免疫學(xué)分冊(cè)，1995；18（3)：130
